Stemedica Cell Technologies, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.stemedica.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
- Conditions
- Covid19
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Stemedica Cell Technologies, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04780685
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Providence Saint John's Health Center - Saint John's Cancer Institute, Santa Monica, California, United States
Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
- Conditions
- Alzheimer Dementia
- Interventions
- Drug: Human Mesenchymal Stem Cells and Lactated Riunger's SolutionOther: Placebo
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Stemedica Cell Technologies, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02833792
- Locations
- 🇺🇸
John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging
- Conditions
- Dermatologic DisordersChronic Effect of Ultraviolet Radiation on Photoaged Skin
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Stemedica Cell Technologies, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01771679
- Locations
- 🇺🇸
eStudy Site, La Mesa, California, United States
🇺🇸Naval Medical Center San Diego, San Diego, California, United States
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
- Conditions
- ST Segment Elevation Myocardial Infarction (STEMI)Allogeneic Mesenchymal Bone Marrow Cells
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Stemedica Cell Technologies, Inc.
- Registration Number
- NCT01770613
- Locations
- 🇺🇸
Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
- Conditions
- Ischemic Stroke
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Stemedica Cell Technologies, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01297413
- Locations
- 🇺🇸
Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States
🇺🇸University of California Irvine Department of Neurology, Orange, California, United States
🇺🇸University of California San Diego Division of Neurological Surgery, San Diego, California, United States